Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

September 2022 | 47 pages | ID: P7BBCC5C438BEN
Global Markets Direct

Abstracts

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

According to the recently published report 'Protein Kinase C Epsilon Type - Drugs In Development, 2022'; Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies.

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Protein kinase C (PKC) is an enzyme belonging to a family of serine%li%and threonine-specific protein kinases that is activated by calcium and the second messenger diacylglycerol. This kinase showed involvement in many different cellular functions, such as neuron channel activation, apoptosis, cardioprotection from ischemia, heat shock response, as well as insulin exocytosis.

The report 'Protein Kinase C Epsilon Type - Drugs In Development, 2022' outlays comprehensive information on the Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 9 and 1 respectively.

Report covers products from therapy areas Central Nervous System, Cardiovascular, Genetic Disorders, Infectious Disease, Oncology and Ophthalmology which include indications Alzheimer's Disease, Ischemia Reperfusion Injury, Traumatic Brain Injury, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Alcohol Addiction, Depression, Dry (Atrophic) Macular Degeneration, Fragile X Syndrome, Human Immunodeficiency Virus (HIV) Infections (AIDS), Ischemic Stroke, Lymphoma, Multiple Sclerosis, Neurology, Parkinson's Disease, Pervasive Developmental Disorder (PDD), Rett Syndrome and Stroke.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)
• The report reviews Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics and enlists all their major and minor projects
• The report assesses Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Overview
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Companies Involved in Therapeutics Development
BryoLogyx Inc
CHS Pharma Inc
Synaptogenix Inc
VM Discovery Inc
Young Therapeutics LLC
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Drug Profiles
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Dormant Products
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Discontinued Products
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Product Development Milestones
Featured News & Press Releases
Jul 26, 2022: Synaptogenix announces changes to scientific advisory board in preparation for phase 2 data
Jul 20, 2022: Synaptogenix advances dosing of first patient in dose optimization clinical trial in preparation for NIH-sponsored, phase 2 Alzheimer's disease trial data
Apr 20, 2022: Synaptogenix concludes subject enrolment in Phase IIb Alzheimer’s trial
Apr 05, 2022: New peer reviewed article demonstrates extended therapeutic potential of Synaptogenix's Bryostatin for Alzheimer's disease
Mar 22, 2022: Synaptogenix to present at Sachs 5th Annual Neuroscience Innovation Forum
Mar 15, 2022: Synaptogenix to present research highlighting potential broad applicability for lead compound bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
Feb 23, 2022: Synaptogenix moves forward with clinical development plans for Bryostatin-1 as a treatment for multiple sclerosis
Feb 01, 2022: Synaptogenix announces publication of peer-reviewed scientific article evidencing Byrostatin-1's improved cognition over baseline in advanced Alzheimer's Disease patients
Jul 26, 2021: Synaptogenix discloses positive results of further Bryostatin trial analyses in presentation at Alzheimer's Association International Conference 2021
Jul 14, 2021: Synaptogenix to present data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline
Jul 07, 2021: Synaptogenix announces regenerative patent award to treat Alzheimer's disease
Jun 09, 2021: Synaptogenix announces phase 2b NIH sponsored Alzheimer's disease trial update
Apr 01, 2021: Synaptogenix announces phase 2b Bryostatin-1 clinical trial update
Feb 04, 2021: Synthetic bryostatin available to expand neurodegenerative indication trials
Oct 13, 2020: BryoLogyx announces completion of world’s first GMP synthesis of bryostatin-1
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by BryoLogyx Inc, 2022
Pipeline by CHS Pharma Inc, 2022
Pipeline by Synaptogenix Inc, 2022
Pipeline by VM Discovery Inc, 2022
Pipeline by Young Therapeutics LLC, 2022
Dormant Projects, 2022
Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022